Baxter International Inc

Baxter has a broad global footprint, manufacturing products in more than 20 countries and selling in over 100 countries. The company reported 2025 sales of $6.12 billion in the United States and $5.12 billion internationally, showing a roughly balanced domestic and international revenue base. International exposure spans emerging markets as well as Western Europe, Canada, Japan, Australia, and New Zealand, which Baxter groups as its rest-of-world markets. Geography matters because the company is exposed to foreign exchange, trade rules, local reimbursement systems, and country-specific supply-chain and regulatory constraints. The exit of IV solutions in China and the impact of Hurricane Helene on the North Cove facility also show how regional operational events can affect product availability and demand.

Baxter faces meaningful execution risk from its ongoing strategic actions, including the Kidney Care sale, the BPS divestiture, and restructuring initiatives that can create dis-synergies, transition costs, and operational disruption. The company also carries substantial competitive and pricing pressure because customers buy on cost-effectiveness, service, and product performance, while healthcare consolidation and reimbursement controls can force price concessions. Supply-chain and manufacturing risks are important because Baxter depends on a global production network and has already experienced disruption from Hurricane Helene and from efforts to reduce its manufacturing footprint. International operations add exposure to foreign exchange, trade policy, import/export restrictions, and local regulatory changes, while product innovation and AI deployment create regulatory, cybersecurity, and intellectual-property risks. Goodwill impairment risk is also material, especially in the Front Line Care reporting unit, where weak demand or macroeconomic softness could trigger further charges.